Engineered immune cells take aim at Hard-to-Treat cancers
NCT ID NCT07266298
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new therapy called NW-101C, which uses a patient's own immune cells (T cells) that have been genetically modified to recognize and attack cancer cells carrying a protein called PRAME. The study will enroll 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the safety of different doses and find the highest dose that can be given safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NW-101C (PRAME-targeted TCR-T cells)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 24 participants, focused on safety and dosing. It is too soon to know if the therapy will shrink tumors or help patients live longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANT TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer hosptial
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.